1型糖尿病胰岛鞘脂代谢异常
该研究探讨鞘脂代谢是否参与人1型糖尿病发病,并测试非诺贝特对NOD小鼠糖尿病的影响。发现新诊断1型糖尿病患者胰岛硫脂苷含量降至对照的23%,8个鞘脂代谢相关基因多态性与遗传易感及胰岛自身免疫程度相关;非诺贝特完全预防NOD小鼠糖尿病,并使半数已发病动物逆转。
要点
- 新诊断1型糖尿病患者胰岛硫脂苷含量为对照的23%,与鞘脂代谢酶表达降低相关。
- 8个鞘脂代谢基因多态性与1型糖尿病遗传易感相关,并与胰岛自身免疫程度相关。
- 非诺贝特完全预防NOD小鼠糖尿病,并使半数已发病动物逆转。
核心结论
- 1型糖尿病存在胰岛鞘脂代谢异常,调节鞘脂代谢可能代表一种新的治疗途径。
研究设计与样本
- 研究采用人胰岛组织免疫组化、免疫荧光和电镜检测硫脂苷,分离人胰岛转录分析,全基因组关联研究和T细胞增殖实验,以及NOD小鼠非诺贝特干预实验。
主要发现
- 新诊断1型糖尿病患者胰岛硫脂苷含量为对照参与者的23%,与鞘脂代谢相关酶表达降低相关。
- 发现8个参与鞘脂代谢的基因多态性(ORMDL3、SPHK2、B4GALNT1、SLC1A5、GALC、PPARD、PPARG和B4GALT1)与1型糖尿病遗传易感相关。
- 这些基因多态性与1型糖尿病患者队列中的胰岛细胞自身免疫程度相关。
- 非诺贝特完全预防NOD小鼠糖尿病,并使半数已发病动物逆转。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Sphingolipids play important roles in beta cell physiology, by regulating proinsulin folding and insulin secretion and in controlling apoptosis, as studied in animal models and cell cultures. Here we investigate whether sphingolipid metabolism may contribute to the pathogenesis of human type 1 diabetes and whether increasing the levels of the sphingolipid sulfatide would prevent models of diabetes in NOD mice. METHODS: We examined the amount and distribution of sulfatide in human pancreatic islets by immunohistochemistry, immunofluorescence and electron microscopy. Transcriptional analysis was used to evaluate expression of sphingolipid-related genes in isolated human islets. Genome-wide association studies (GWAS) and a T cell proliferation assay were used to identify type 1 diabetes related polymorphisms and test how these affect cellular islet autoimmunity. Finally, we treated NOD mice with fenofibrate, a known activator of sulfatide biosynthesis, to evaluate the effect on experimental autoimmune diabetes development. RESULTS: We found reduced amounts of sulfatide, 23% of the levels in control participants, in pancreatic islets of individuals with newly diagnosed type 1 diabetes, which were associated with reduced expression of enzymes involved in sphingolipid metabolism. Next, we discovered eight gene polymorphisms (ORMDL3, SPHK2, B4GALNT1, SLC1A5, GALC, PPARD, PPARG and B4GALT1) involved in sphingolipid metabolism that contribute to the genetic predisposition to type 1 diabetes. These gene polymorphisms correlated with the degree of cellular islet autoimmunity in a cohort of individuals with type 1 diabetes. Finally, using fenofibrate, which activates sulfatide biosynthesis, we completely prevented diabetes in NOD mice and even reversed the disease in half of otherwise diabetic animals. CONCLUSIONS/INTERPRETATION: These results indicate that islet sphingolipid metabolism is abnormal in type 1 diabetes and suggest that modulation may represent a novel therapeutic approach. DATA AVAILABILITY: The RNA expression data is available online at https://www.dropbox.com/s/93mk5tzl5fdyo6b/Abnormal%20islet%20sphingolipid%20metabolism%20in%20type%201%20diabetes%2C%20RNA%20expression.xlsx?dl=0 . A list of SNPs identified is available at https://www.dropbox.com/s/yfojma9xanpp2ju/Abnormal%20islet%20sphingolipid%20metabolism%20in%20type%201%20diabetes%20SNP.xlsx?dl=0 .
引用
- Holm LJ, Krogvold L, Hasselby JP, et al. Abnormal islet sphingolipid metabolism in type 1 diabetes. Diabetologia. 2018. PMID: 29671030. doi:10.1007/s00125-018-4614-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。